West Announces the Commercial Introduction of a Novel Intradermal Adapter for Disposable Syringes
Designed to help improve consistency and reliability of intradermal injections
EXTON, Pa., Feb. 27, 2013 /PRNewswire/ — West Pharmaceutical Services, Inc. (NYSE: WST), a leading global developer and manufacturer of components and systems for injectable drug delivery, announces the commercial introduction of its ID Adapter. West acquired a license to the technology in 2010 and has completed the product development and first phase of commercial scale-up at its manufacturing center in Arizona. West recently received 510K clearance for the ID Adapter from the United States Food and Drug Administration.
The adapter is designed to help improve the consistency and reliability of intradermal injections for vaccines and other injectable drugs. The system will complement West’s portfolio of prefilled syringe offerings and technologies. Correctly administered ID injections can help conserve the supply of high-value vaccines and can provide patients significant benefit through more reliable injection. The ID Adapter will provide an alternative to the Mantoux method, the industry standard for intradermal injection since 1907. The Mantoux method is accomplished by inserting the needle into the skin at a very shallow angle. It requires extensive training and experience to perform correctly and consistently, whereas the ID Adapter enables this process to be carried out more easily and with greater reliability.
“We are delighted to offer our customers a solution which can improve reliability and performance of intradermal injections and meet growing market demands in this area,” said John Paproski, President, Pharmaceutical Delivery Systems, West. Click here for more information on the ID Adapter technology.
West works side-by-side with its healthcare partners from concept to the patient, designing and manufacturing packaging, diagnostic and delivery systems that promote the efficiency, reliability and safety of their products. Every day, West is leading the way with cutting-edge technologies and quality systems, a thorough understanding of global regulatory compliance, and an unmatched and growing knowledge base of relevant pharmaceutical product testing, development and packaging. Based in Exton, Pa., West supports its customers from sales, manufacturing, customer support and research and development locations in North and South America, Europe, Asia and Australia. Established in 1923, West’s 2012 sales were $1.3 billion.
WestPharma will be joining us at the World Vaccine Congress Washington 2013, on the 16-18 April. Book now to see them there >